Prof. Friedrich Breyer

Chair  of  Economic  and Social Policy,  University of Konstanz
(Germany),  Economics Department.

Member of the executive board and chairman, health economics committee
of the association of German-speaking economists (Verein für Socialpolitik);
member  of  the  advisory  board of the Federal  Ministry of  Economics and
Technology  (Germany);  Research  Professor  at  the  German  Institute of
Economic Research in Berlin;  author of a major  health economics textbook.


Prof. Martin J. Buxton

Professor  and  Director  of  the  Health Economics Research
Group (HERG)  at Brunel University,  London.

Over  20  years  experience in the methods and practice  of  economic  eval-
uation in health care; previously member of the Appraisal Committee of the
National  Institute for Clinical Excellence (NICE);  member of the Reference
Group  established by NICE to review the new Single Technology Appraisal
(STA) process.


Prof. J. Jaime Caro

Adjunct Professor of Medicine and of Epidemiology & Biosta-
tistics at McGill University, Montréal, Canada; Scientific Direc-
tor of Caro Research (now part of UBC), Montréal, QC, and Boston, MA

Chairman  of the  international health economic  advisory board of the  Ger-
man  Institute  for Quality and Efficiency in Health Care (IQWiG);  main re-
search interests in the field of health technology assessment, in particular in
the design of economic models and related analytic techniques


Prof. Gérard de Pouvourville

Professor  of  Health Economics and Department Chair / Se-
nior  Research  Director  at  ESSEC,  Business  School Paris –
Singapore,  Paris,  France.

Chairman  of  the  French Health Economists Association,  Vice Chairman of
the  National Observatory  for  Drug  Prescription  and Use,  member of the
board of INSERM, the French National Health Research Institute; his main
fields of research include health technology assessments including economic
evaluation

Prof. Sören Holm

Professorial Fellow in Bioethics at Cardiff Law School, Cardiff
University, Wales.

Professor of  Medical Ethics  at the Universiy of Olso,  Norway;  editor-in-
chief  of  The Jornal of Medical Ethics;  member  of the  Danish Council  of
Ethics from 1994 to 1999;  currently  President-Elect of the European So-
ciety for the Philosophy of Medicine and Health Care.


Wolfgang Kaesbach

Board  member of the  German Federal  Association of Com-
pany  Sickfunds  (Bundesverband  der  Betriebskrankenkas-
sen, BKK).

Member of the Medicine Evaluation Committee (MEDEV), European Social
Health  Insurance Forum;  head  of department  of pharmaceutical and me-
dical  products  at  BKK,  the  lead  organization  of  the  German  Statutory
Health Insurance on pharmaceutical pricing and reimbursement.


Prof. Panos Kanavos

Senior  Lecturer  in  International  Health  Policy  and  Merck
Fellow in Pharmaceutical Economics at the London School of
Economics   (LSE)   and    Professor   at   the   University   of
Lausanne , Switzerland

Panos Kanavos  has acted as  advisor to the World Bank,  the World  Health
Organization, the European Commission, the Organisation for Economic Co-
operation and Development (OECD),  the American Association for  Retired
Persons  and Ministries  of  Health  as  well as other governmental and non-
governmental organizations in over 21 transition and developing countries.


PD Dr. Peter Kolominsky-Rabas

Head of the  Department for Health  Economics  at  the Ger-
man   Institute   for  Quality  and  Efficiency  in  Health  Care
(IQWiG),  Cologne  (Germany).

Founder and  previous Scientific Director of the Interdisciplinary Center for
Public  Health Studies at the University of Erlangen  (Germany);  Chairman
of the Health Economics and Outcomes Research Committee of the German
Stroke Association (DSG);  Managing Board Member of the Bavarian Public
Health Network.


Prof. Peter J. Neumann

Professor  of  Medicine and  Director  of  the  Center  for  the
Evaluation  of Value  and Risk  in Health at Tufts  University /
New England Medical Center, Boston (Massachussetts).

Past  President  of  the  International  Society  for  Pharmacoeconomics  and
Outcomes Research (ISPOR)  and  trustee  of the Society for  Medical Deci-
sion  Making;  directing  a  project  to develop  a  comprehensive  registry of
cost-effectiveness analyses in health care.


Prof. Erik Nord

Senior   Researcher  at  the  Norwegian  Institute  of  Public
Health,  Oslo  (Norway),  since  2003  in  the Department of Mental Health.

Assignments for the OECD, the WHO, and the Norwegian National Council
for  Priority Setting in Health Care;  long-standing research interests in me-
thods  and  procedures for economic evaluation and priority setting;  author
of a textbook on “cost-value" analysis in health care.


Dr. Ulf Persson

Research Director at The Swedish Institute for Health Eco-
nomics (IHE), Lund (Sweden).

Over 20 years research experience in the development and application of
economic evaluation methods in health care,  with particular regard to the
introduction and utilization of medical technologies.


Prof. Jeff Richardson

Professor  in the  Faculty of Business  and  Economics at
Monash  University   ( Melbourne  /  Clayton,  Victoria );
Foundation Director of the Centre for Health Economics (CHE).

President of the  Australian  Health  Economists’ Group  from  1984  to
1991; member of the Pharmaceutical Remuneraton Tribunal in Austra-
lia;  member of the editorial boards of five leading health economic jour-
nals.


Prof. Michael Schlander1

Founding Chairman of the  Institute for Innovation &  Valua-
tion in  Health  Care  (  );  Professor  of  Health  Care
Management at the  University of Applied Economic Sciences
Ludwigshafen (Germany);

Health Economist at the Mannheim  Institute  of  Public Health,  Social  and
Preventive Medicine (University of Heidelberg);  over 15 years experience
in  executive  management  roles  (in  clinical  research  and marketing & as
CEO)  in the international pharmaceutical industry;  author  of an  in-depth
analysis of the NICE multiple technology appraisal process.


Dr. Darcey Terris

Postdoctoral  Fellow at the Mannheim  Institute  for Public
Health, Social and Preventive Medicine at the University of Heidelberg (Germany).

Main research interests include quality management in health care and preference-based measures of health benefits.

Koen Torfs

Vice President, Health Economics & Public Affairs, Janssen-
Cilag GmbH (Neuss, Germany).

Over 20 years experience in the economic evaluation of health care inter-
ventions.


Prof. Rosalie Viney

Associate Professor and Deputy Director at the Centre for
Health  Economics  Research  &  Evaluation,  University  of
Technology, Sydney, New South Wales.

Chair  of  the  Australian  Pharmaceutical  Benefits  Advisory  Committee
(PBAC)’s Economics Sub-Committee; research areas include utilization of
health  services,  valuation  of  health  outcomes,  the use  of economic eva-
luation in resource allocation, and measurement of individual’s preferences
for health care services.


1  Scientific Program Director